Heart failure with preserved ejection fraction (HFpEF) is a complex condition affecting millions of people worldwide, where the heart muscle remains relatively strong but becomes stiff and unable to fill properly. While standard medications have shown limited success, recent breakthroughs offer new hope for patients struggling with shortness of breath, fatigue, and fluid buildup.

Understanding Treatment Goals and Approaches

When someone receives a diagnosis of heart failure with preserved ejection fraction, the primary goals of treatment focus on relieving troublesome symptoms like breathlessness and swelling, improving daily function and quality of life, and preventing hospital admissions. Unlike other forms of heart disease where medications can dramatically improve survival, HFpEF treatment has historically been more challenging, with therapy primarily aimed at making patients feel better and keeping them out of the hospital.^[1][2]

Treatment approaches must be highly individualized because HFpEF is not a single disease but rather a syndrome with many different causes and contributing factors. What works well for one patient may not help another. The specific treatment plan depends on several factors, including the severity of symptoms, the presence of other medical conditions such as high blood pressure or diabetes, and how the person’s body responds to initial therapies.^[3]

Medical societies and heart failure experts have developed guidelines for managing this condition, though these recommendations have evolved significantly in recent years as new research emerges. Importantly, alongside established therapies approved by regulatory authorities, ongoing clinical trials are testing promising new drugs and approaches that may expand treatment options in the future.^[7]

The cornerstone of HFpEF management involves a combination of lifestyle modifications, treatment of underlying conditions that contribute to heart stiffness, and careful use of medications. Because the condition often affects older adults who may have multiple health problems, treatment requires coordination among different healthcare providers and attention to the whole person, not just the heart.^[6]

Standard Treatment Approaches

The foundation of standard HFpEF treatment centers on managing symptoms and addressing the medical conditions that contribute to the syndrome. Unlike heart failure with reduced ejection fraction, where specific medications have proven to reduce mortality, HFpEF has historically lacked such breakthrough drugs, though this paradigm has recently begun to change.^[3]

Diuretics, commonly known as water pills, remain the most consistently useful medication for HFpEF. These drugs work by helping the kidneys remove excess fluid from the body, thereby reducing the buildup of fluid in the lungs, abdomen, and legs that causes swelling and breathing difficulty. Patients experiencing symptoms of fluid overload should receive diuretic therapy, with the dose adjusted based on weight changes and symptom relief. While diuretics improve how patients feel, they have not been shown to extend survival.^[3][9]

Blood pressure control represents another critical component of standard therapy. Hypertension affects 80 to 90 percent of patients with HFpEF and contributes significantly to heart muscle stiffening. When high blood pressure is present, it should be treated according to evidence-based hypertension guidelines. Various classes of blood pressure medications may be used, though clinicians must balance effective pressure control against the risk of lowering blood pressure too much, which can cause dizziness and weakness.^[1][3]

For patients with atrial fibrillation, a common heart rhythm problem in HFpEF, treatment typically involves a rate-control strategy to keep the heart from beating too quickly, along with appropriate blood-thinning medication to prevent stroke. The irregular heart rhythm can worsen symptoms because the stiff heart depends heavily on properly timed atrial contraction to fill adequately.^[3]

When coronary artery disease coexists with HFpEF, revascularization procedures such as stenting or bypass surgery should be considered for patients who have appropriate indications. Restoring blood flow to the heart muscle can sometimes improve both heart function and symptoms.^[3][9]

Recent guidelines now recommend sodium-glucose cotransporter-2 (SGLT2) inhibitors, a newer class of medication originally developed for diabetes, as an important treatment option. These drugs have emerged as the first pharmacologic agents to show meaningful benefit across the spectrum of heart failure, including HFpEF. They work through multiple mechanisms beyond their blood sugar-lowering effects, including improving how the kidneys handle sodium and reducing inflammation and stress on the heart muscle.^[7][11]

Treatment duration for HFpEF is typically long-term or lifelong, as the condition represents chronic heart muscle changes that cannot be fully reversed. Medications and treatment strategies may need adjustment over time based on symptom progression, development of new medical problems, or changes in how well the patient tolerates therapy. Regular monitoring through clinic visits, weight checks, and sometimes blood tests helps guide these adjustments.^[7]

Side effects from standard treatments vary by medication class. Diuretics can cause excessive urination, low potassium levels, kidney function changes, and dizziness from low blood pressure. Blood pressure medications may cause fatigue, dizziness, or, depending on the specific drug, cough or swelling. SGLT2 inhibitors can increase the risk of genital yeast infections and, rarely, a serious condition called ketoacidosis. Patients should discuss potential side effects with their healthcare team and report any concerning symptoms promptly.^[7]

Lifestyle Modifications as Treatment

Beyond medications, lifestyle changes play a crucial role in managing HFpEF. Exercise training, particularly a combination of endurance and resistance activities, has proven helpful for improving symptoms and quality of life. Patients with HFpEF should be referred for supervised exercise-based cardiac rehabilitation programs when available. These structured programs provide safe, gradual increases in physical activity tailored to individual capabilities.^[3][9]

Dietary modifications, especially limiting sodium intake, can help reduce fluid retention and ease breathing difficulty. Patients may also receive guidance on restricting total fluid consumption if they experience significant fluid overload. Weight management is particularly important, as obesity represents both a risk factor for developing HFpEF and a contributor to worsening symptoms. For overweight patients, even modest weight loss can improve how they feel and function.^[16]

Multidisciplinary care teams that coordinate treatment across different specialties have shown promise in helping patients manage the complex demands of living with HFpEF. These teams may include cardiologists, primary care physicians, nurses, dietitians, pharmacists, and exercise specialists working together to optimize all aspects of care.^[3][6]

Innovative Therapies in Clinical Trials

Because standard treatments for HFpEF have historically offered limited benefit beyond symptom control, researchers have actively investigated new therapeutic approaches through clinical trials. These studies test whether innovative medications, devices, or treatment strategies can improve outcomes for patients living with this challenging condition.^[6]

The most significant recent breakthrough in HFpEF research involves SGLT2 inhibitors, which have now transitioned from experimental to recommended therapy. Multiple Phase III clinical trials have demonstrated that these drugs reduce hospitalizations for heart failure and improve quality of life in patients with HFpEF. These large-scale trials compared SGLT2 inhibitors against placebo in thousands of patients across multiple countries, providing strong evidence of benefit.^[7][11]

The mechanism by which SGLT2 inhibitors help HFpEF patients extends beyond their original purpose as diabetes medications. These drugs appear to reduce the heart’s energy demands, decrease inflammation throughout the cardiovascular system, improve how blood vessels function, and help the heart muscle become less stiff. They also promote beneficial changes in kidney function and fluid handling that complement their cardiovascular effects.^[11]

Clinical investigators continue to study angiotensin receptor-neprilysin inhibitors (ARNIs), a combination medication that blocks a hormone system causing blood vessel constriction while simultaneously preventing breakdown of beneficial peptides that promote blood vessel relaxation. While these drugs have proven highly effective for heart failure with reduced ejection fraction, their role in HFpEF remains under investigation. Some Phase III trials have suggested potential benefit in selected HFpEF patients, particularly those with lower-normal ejection fractions, though results have been mixed.^[7]

Researchers are exploring novel approaches targeting the fundamental processes that make the heart muscle stiff in HFpEF. At the cellular level, cardiac muscle cells in HFpEF patients become thicker and shorter than normal cells, and the supporting framework of the heart accumulates excess collagen, contributing to stiffness. Some experimental therapies aim to prevent or reverse these structural changes. Additionally, scientists have identified reductions in small blood vessels supplying the heart muscle in HFpEF patients, prompting investigation of therapies to improve microvascular function.^[1]

Device-based interventions represent another area of active clinical trial investigation. Some studies are testing devices that create a small opening between the left and right sides of the heart to reduce pressure buildup during exercise. Other trials examine whether devices that modulate nerve signals to the kidneys or cardiovascular system might improve symptoms. These innovative approaches typically undergo Phase I and II testing to establish safety and early efficacy signals before advancing to larger Phase III trials.^[11]

Clinical trials for HFpEF often focus on specific patient subgroups or phenotypes, recognizing that the syndrome encompasses multiple disease processes. Some trials specifically enroll patients with HFpEF and obesity, others focus on those with kidney disease, and still others target patients with specific markers of inflammation. This phenotype-specific approach reflects growing understanding that HFpEF treatment may need to be tailored to the underlying causes in individual patients.^[11]

Trial locations for HFpEF research span the globe, with major studies conducted in the United States, Europe, and increasingly in Asia and other regions. Patient eligibility for clinical trials typically requires confirmed HFpEF diagnosis through echocardiography showing preserved ejection fraction along with evidence of elevated heart pressures. Many trials exclude patients with certain severe medical conditions or those taking medications that might interfere with the experimental treatment. Interested patients should discuss clinical trial participation with their cardiologists, who can determine eligibility and provide information about available studies.^[6]

Most Common Treatment Methods

• Diuretics (Water Pills)
  • Remove excess fluid from the body to reduce swelling and breathing difficulty
  • The most consistently effective medication for symptom relief in HFpEF
  • Dose adjusted based on weight changes and symptom control
  • Required for patients showing signs of fluid overload
• Blood Pressure Management
  • Critical since 80-90% of HFpEF patients have hypertension
  • Treated according to evidence-based hypertension guidelines
  • Helps prevent further heart muscle stiffening
  • Various medication classes may be used based on individual needs
• SGLT2 Inhibitors
  • Newer class originally developed for diabetes
  • First medications to show meaningful benefit for HFpEF outcomes
  • Work through multiple mechanisms including reducing inflammation and improving kidney function
  • Reduce hospitalizations and improve quality of life
  • Now recommended in current treatment guidelines
• Exercise-Based Cardiac Rehabilitation
  • Combination of endurance and resistance training
  • Supervised programs tailored to individual capabilities
  • Improves symptoms and quality of life
  • Safe and effective when properly structured
• Treatment of Atrial Fibrillation
  • Rate-control strategy to manage heart rhythm
  • Anticoagulation therapy to prevent stroke
  • Important because irregular rhythm worsens HFpEF symptoms
• Revascularization Procedures
  • Stenting or bypass surgery for patients with coronary artery disease
  • Restores blood flow to heart muscle
  • Can improve function and symptoms when appropriately indicated
• Lifestyle Modifications
  • Sodium restriction to reduce fluid retention
  • Weight management, especially for obese patients
  • Fluid limitation when significant overload present
  • Smoking cessation and alcohol moderation
• Multidisciplinary Care
  • Coordinated treatment across multiple specialties
  • Teams include cardiologists, nurses, dietitians, pharmacists, and exercise specialists
  • Addresses the complex needs of HFpEF patients
  • Improves management of multiple coexisting conditions